89bio Inc (NAS:ETNB)

$ 8.855 0.385 (4.55%) Market Cap: 937.83 Mil Enterprise Value: 433.80 Mil PE Ratio: 0 PB Ratio: 1.73 GF Score: 36/100

89Bio Inc at H.C. Wainwright & Co LLC 7th Annual NASH Investor Conference (Virtual) Transcript
Oct 24, 2023
89Bio Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
89Bio Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
89Bio Inc at Bank of America Global Healthcare Conference Transcript
May 09, 2023
89Bio Inc Topline Results from Phase 2b ENLIVEN Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis - Corporate Call Transcript
Mar 22, 2023
89Bio Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 15, 2023
89Bio Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 17, 2022
89Bio Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
89Bio Inc at Bank of America Healthcare Conference Transcript
May 10, 2022

89Bio Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2023 / 12:30PM GMT

Release Date Price: $17.64 (-0.17%)

Transcript

Brian Abrahams

RBC Capital Markets - Analyst

All right. Good morning, everyone. I'm Brian Abrahams, one of the senior biotech analysts here at RBC. We're really pleased to have our next presenting company, 89bio represented by their CFO, Ryan Martins. Ryan, thanks so much for joining us today.

Ryan Martins

89bio, Inc. - CFO

Thanks, Brian. Excited to be here, and thanks for the invitation.

Brian Abrahams

RBC Capital Markets - Analyst

Of course. So maybe let's start bigger picture. I was wondering if you could maybe catch everybody up on the latest status of pegozafermin, the key findings from the recent Phase 2b study you reported -- Phase 2b studies you reported in NASH and SHTG and the overall next steps? And then would love to dive into some of those details after.

Ryan Martins

89bio, Inc. - CFO

Yeah. Perfect. Just to make sure everyone's familiar with the company, we are a company that's late clinical stage that's focused on developing drugs for liver and cardio

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.